Novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and diabetes—Good or excellent?

Aviv A. Shaul; Alon Eisen

doi:10.1002/dmrr.2893

Novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and diabetes—Good or excellent?

Aviv A. Shaul, Alon Eisen^*

^*Corresponding author for this work

Cardiology

Tel Aviv University

Research output: Contribution to journal › Comment/debate

Original language	English
Article number	e2893
Journal	Diabetes/Metabolism Research and Reviews
Volume	33
Issue number	5
DOIs	https://doi.org/10.1002/dmrr.2893
State	Published - Jul 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/dmrr.2893

Cite this

@article{e601447877c840048e4cbb94a6545256,

title = "Novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and diabetes—Good or excellent?",

author = "Shaul, {Aviv A.} and Alon Eisen",

year = "2017",

month = jul,

doi = "10.1002/dmrr.2893",

language = "אנגלית",

volume = "33",

journal = "Diabetes/Metabolism Research and Reviews",

issn = "1520-7552",